Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -47.96% is 53% above its 5-year average of -102.50%, near the high end of its 5-year range (-811.90%–4.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 49.70% above its 12-month average of -95.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -47.96%.
RETURN ON EQUITY (ROE)
-47.96%
RETURN ON EQUITY (ROE) AVG TTM
-95.34%
RETURN ON EQUITY (ROE) AVG 3Y
-108.51%
RETURN ON EQUITY (ROE) AVG 5Y
-102.50%
RETURN ON EQUITY (ROE) AVG 10Y
-52.92%
RETURN ON EQUITY (ROE) AVG 15Y
-15.48%
RETURN ON EQUITY (ROE) AVG 20Y
-2.17%
CURRENT VS TTM AVG
+49.70%
CURRENT VS 3Y AVG
+55.80%
CURRENT VS 5Y AVG
+53.21%
CURRENT VS 10Y AVG
+9.38%
CURRENT VS 15Y AVG
-209.74%
CURRENT VS 20Y AVG
-2112.60%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-14.16%
vs the sector median at left
Veru Inc.
Market Cap
$40.21M
Return on Equity (ROE)
-47.96%
TTM Avg
-95.34%
3Y Avg
-108.51%
5Y Avg
-102.50%
Market Cap
$40.42M
Return on Equity (ROE)
-66.47%
TTM Avg
-61.13%
3Y Avg
-30.57%
5Y Avg
-24.45%
Market Cap
$39.15M
Return on Equity (ROE)
-83.03%
TTM Avg
-44.32%
3Y Avg
5.07%
5Y Avg
17.23%
Market Cap
$38.52M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
Market Cap
$38.11M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$41.95M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$37.59M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$43.65M
Return on Equity (ROE)
-102.45%
TTM Avg
30.59%
3Y Avg
217.16%
5Y Avg
155.68%
Market Cap
$42.93M
Return on Equity (ROE)
-161.19%
TTM Avg
-40.99%
3Y Avg
-40.41%
5Y Avg
-33.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veru Inc. (VERU) | $40.21M | -47.96% | -95.34% | -108.51% | -102.50% |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.42M | -66.47% | -61.13% | -30.57% | -24.45% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | -83.03% | -44.32% | 5.07% | 17.23% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.52M | -140.36% | -216.21% | -112.57% | -76.80% |
| Nephros, Inc. (NEPH)vs › | $38.11M | 14.51% | 6.28% | -34.57% | -35.24% |
| Precipio, Inc. (PRPO)vs › | $41.95M | -8.23% | -18.98% | -38.34% | -43.89% |
| Incannex Healthcare Limited (IXHL)vs › | $37.59M | -28.65% | -189.41% | -194.44% | -158.64% |
| BioStem Technologies, Inc. (BSEM)vs › | $43.65M | -102.45% | 30.59% | 217.16% | 155.68% |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.93M | -161.19% | -40.99% | -40.41% | -33.61% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.70M | -160.05% | -184.57% | -168.71% | -141.15% |
ROE
-48.0%
ROA
-36.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -47.96% |
| 2026-03-31 | -40.11% |
| 2025-12-31 | -51.49% |
| 2025-09-30 | -123.97% |
| 2025-06-30 | -213.17% |
| 2025-03-31 | -172.69% |
| 2024-12-31 | -144.48% |
| 2024-09-30 | -116.97% |
| 2024-06-30 | -99.42% |
| 2024-03-31 | -73.20% |
| 2023-12-31 | -110.18% |
| 2023-09-30 | -443.59% |
| 2023-06-30 | -349.49% |
| 2023-03-31 | -811.90% |
| 2022-12-31 | -236.47% |
| 2022-09-30 | -101.18% |
| 2022-06-30 | -40.26% |
| 2022-03-31 | -20.25% |
| 2021-12-31 | -10.95% |
| 2021-09-30 | 4.86% |
| 2021-06-30 | -0.09% |
| 2021-03-31 | -0.31% |
| 2020-12-31 | 3.20% |
| 2020-09-30 | -63.01% |
| 2020-06-30 | -24.71% |
| 2020-03-31 | -31.98% |
| 2019-12-31 | -44.44% |
| 2019-09-30 | -37.17% |
| 2019-06-30 | -48.58% |
| 2019-03-31 | -65.68% |
| 2018-12-31 | -59.19% |
| 2018-09-30 | -81.20% |
| 2018-06-30 | -52.13% |
| 2018-03-31 | -27.96% |
| 2017-12-31 | -21.24% |
| 2017-09-30 | -13.65% |
| 2017-06-30 | -17.32% |
| 2017-03-31 | -12.89% |
| 2016-12-31 | -7.13% |
| 2016-09-30 | 1.02% |
| 2016-06-30 | 7.88% |
| 2016-03-31 | 9.75% |
| 2015-12-31 | 14.49% |
| 2015-09-30 | 13.12% |
| 2015-06-30 | 9.51% |
| 2015-03-31 | 9.87% |
| 2014-12-31 | 6.06% |
| 2014-09-30 | 8.67% |
| 2014-06-30 | 33.10% |
| 2014-03-31 | 33.00% |
| 2013-12-31 | 41.93% |
| 2013-09-30 | 45.67% |
| 2013-06-30 | 59.62% |
| 2013-03-31 | 68.61% |
| 2012-12-31 | 66.06% |
| 2012-09-30 | 63.17% |
| 2012-06-30 | 58.19% |
| 2012-03-31 | 54.75% |
| 2011-12-31 | 45.25% |
| 2011-09-30 | 32.23% |
| 2011-06-30 | 47.55% |
| 2011-03-31 | 42.46% |
| 2010-12-31 | 50.74% |
| 2010-09-30 | 41.76% |
| 2010-06-30 | 28.91% |
| 2010-03-31 | 33.94% |
| 2009-12-31 | 34.00% |
| 2009-09-30 | 50.45% |
| 2009-06-30 | 62.04% |
| 2009-03-31 | 67.84% |
| 2008-12-31 | 65.98% |
| 2008-09-30 | 51.16% |
| 2008-06-30 | 42.31% |
| 2008-03-31 | 38.19% |
| 2007-12-31 | 33.39% |
| 2007-09-30 | 22.74% |
| 2007-06-30 | 10.12% |
| 2007-03-31 | 4.96% |
| 2006-12-31 | -0.09% |
| 2006-09-30 | 5.91% |
| 2006-06-30 | 2.20% |
| 2006-03-31 | -2.58% |
| 2005-12-31 | -2.27% |
| 2005-09-30 | -40.96% |
| 2005-06-30 | -58.43% |
| 2005-03-31 | -49.70% |
| 2004-12-31 | -87.08% |
| 2004-09-30 | -110.60% |
| 2004-06-30 | -121.11% |
| 2004-03-31 | -191.05% |
| 2003-09-30 | -480.64% |
| 2003-06-30 | -260.45% |
